Lipoprotein-based Therapeutic Approach to Combat Breast Cancer
ISEF · 2018 Translational Medical Science
Overview
Lack of effective treatment and substantial side effects of current chemotherapy have resulted in poor prognosis for triple-negative breast cancer (TNBC) patients. To avoid these side effects and to increase the quality-of-life of TNBC patients, targeted therapy in the form of high-density lipoprotein (rHDL) nanoparticles has been explored in this project. The drug (lapatinib) is released from these nanoparticles only when they are attached to a gatekeeper molecule (SR-B1) exclusively present on cancer cells with the exception of hepatocytes. The objective of the project was to determine whether lapatinib delivered by rHDL nanoparticles (rHDL-Lapatinib) via SR-B1 could inhibit cancer cell growth and proliferation. In this study, Western blot analysis showed high SR-B1 expression, which varied from 15- to 354-fold in three different breast cancer cell lines compared to normal cardiac cells. Based on the cell viability assays and IC50 values, the rHDL-Lapatinib nanoparticles were 1.22-, 2.4-, and 8.8-fold more effective than free lapatinib in killing MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cells, respectively. Moreover, the scratch-wound assays indicated that the rHDL-Lapatinib nanoparticles inhibited migration of cancer cells in-vitro. This result was in accordance with expression levels of Matrix Metalloproteinase 9 (MMP-9), which is a major contributor to cancer metastasis. MMP-9 levels were found to be 4- to 8-fold higher in breast cancer cells relative to normal cells. Preliminary evidence from these studies shows the potential of rHDL as a targeted drug delivery platform to deliver current chemotherapy drugs with substantially lower side effect, thereby enhancing quality-of-life for TNBC patients.
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2024
TNBCnano: Novel Layer-By-Layer Nanoparticles for Systemic Combination Delivery of MRP1 siRNA and Doxorubicin for Triple-Negative Breast Cancer Treatment
ISEF · 2014
Lipoproteins as a Vehicle for Targeted and Selective Delivery of Hydrophobic Drugs to Cancer Cells
ISEF · 2019
Reconstituted High-Density Lipoproteins for the Treatment of Pediatric Cancer
ISEF · 2020
Targeted Breast Cancer Therapy Using Nanoparticles Modified by Tumor-Homing Peptides
ISEF · 2019
Targeted Drug Delivery for Drug Resistant Cancer
ISEF · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2023
Smart Theranostic Lipid-Based Nanoparticles for Breast Cancer Treatment Using Hydrophobic Cytostatics
ISEF · 2023
Cure of Breast Cancer-Year 6: Novel Approaches in the Therapy of Metastatic Breast Cancer Using Clinical Databases and 3D Organoid Model
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair